RANKINGS

POPULAR STOCKS

Cerus Corporation

NasdaqGM:CERS

Location

United States

Market Cap

USD 252.33 M

Share Price

USD 1.32

Avg Daily Volume

1,551,075

Change (1 day)

-3.65%

Change (1 year)

-21.43%

Change (YTD)

-14.29%

Cerus Corporation Revenue for the Trailing 12 Months (TTM) ending March 31, 2025: USD 185.14 M

Cerus Corporation Revenue is USD 185.14 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 13.06% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Cerus Corporation Revenue for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 163.76 M, a 5.26% change year over year.
  • Cerus Corporation Revenue for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 155.58 M, a 7.35% change year over year.
  • Cerus Corporation Revenue for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 144.92 M, a 49.89% change year over year.
  • Cerus Corporation Revenue for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 96.69 M, a 27.63% change year over year.
Key data
Date Revenue Revenue Gross Profit Operating Income
Market news
NasdaqGM: CERS

Cerus Corporation

CEO Mr. William M. Greenman
IPO Date Jan. 31, 1997
Location United States
Headquarters 1220 Concord Avenue
Employees 614
Sector 🏥 Health Care
Industries
Telehealth
🧬 Biotechnology
💳 Credit Cards & Payments
🍔 Meat
🧾 Point-Of-Sale (POS)
Description

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

Similar companies

BSX

Boston Scientific Corporation

USD 104.29

0.16%

SHL.DE

Siemens Healthineers AG

USD 54.76

0.58%

207940.KS

Samsung Biologics Co.,Ltd.

USD 738.76

0.66%

CTSH

Cognizant Technology Solutions Corporation

USD 76.98

-0.79%

GEHC

GE HealthCare Technologies Inc.

USD 72.75

1.07%

4543.T

Terumo Corporation

USD 18.48

0.13%

NTRA

Natera, Inc.

USD 164.16

-4.49%

LH

Laboratory Corporation of America Holdings

USD 258.70

-1.46%

7203.SR

Elm Company

USD 264.26

4.20%

BAX

Baxter International Inc.

USD 30.61

0.07%

TORNTPHARM.NS

Torrent Pharmaceuticals Limited

USD 37.11

-1.05%

ICLR

ICON Public Limited Company

USD 145.91

-1.77%

RGC

Regencell Bioscience Holdings Limited

USD 21.73

-5.32%

600010.SS

Inner Mongolia Baotou Steel Union Co., Ltd.

USD 0.25

0.22%

ASND

Ascendis Pharma A/S

USD 173.00

-3.41%

6869.T

Sysmex Corporation

USD 17.09

0.34%

EXAS

Exact Sciences Corporation

USD 51.92

1.47%

CTEC.L

ConvaTec Group Plc

USD 3.96

0.77%

WAY

Waystar Holding Corp.

USD 39.00

0.75%

300832.SZ

Shenzhen New Industries Biomedical Engineering Co., Ltd.

USD 8.00

0.06%

GH

Guardant Health, Inc.

USD 49.90

-0.18%

DIA.MI

DiaSorin S.p.A.

USD 109.19

-0.66%

3347.HK

Hangzhou Tigermed Consulting Co., Ltd.

USD 4.54

-5.44%

LNTH

Lantheus Holdings, Inc.

USD 80.55

-0.49%

688617.SS

APT Medical Inc.

USD 41.26

1.54%

SOL.MI

SOL S.p.A.

USD 54.04

-1.80%

TMDX

TransMedics Group, Inc.

USD 128.58

-3.06%

ADMA

ADMA Biologics, Inc.

USD 17.60

-1.40%

LAURUSLABS.NS

Laurus Labs Limited

USD 7.78

-0.11%

002065.SZ

DHC Software Co.,Ltd.

USD 1.31

0.86%

IPCALAB.NS

Ipca Laboratories Limited

USD 15.81

0.19%

INSP

Inspire Medical Systems, Inc.

USD 132.00

-0.42%

MCOV-B.ST

Medicover AB (publ)

USD 25.73

3.87%

600566.SS

Hubei Jumpcan Pharmaceutical Co., Ltd.

USD 3.93

1.22%

HAE

Haemonetics Corporation

USD 73.40

0.46%

002603.SZ

Shijiazhuang Yiling Pharmaceutical Co., Ltd.

USD 1.97

-0.21%

PFIZER.NS

Pfizer Limited

USD 65.60

1.28%

300676.SZ

BGI Genomics Co., Ltd.

USD 6.92

-0.27%

LALPATHLAB.NS

Dr. Lal PathLabs Limited

USD 32.09

-0.24%

ERIS.NS

Eris Lifesciences Limited

USD 18.85

-0.41%

LIVN

LivaNova PLC

USD 45.87

-0.35%

7030.SR

Mobile Telecommunications Company Saudi Arabia

USD 2.78

-0.17%

300529.SZ

Jafron Biomedical Co.,Ltd.

USD 2.99

0.64%

600739.SS

Liaoning Cheng Da Co., Ltd.

USD 1.54

-0.42%

VIMIAN.ST

Vimian Group AB (publ)

USD 4.23

-3.41%

ALIF-B.ST

AddLife AB (publ)

USD 18.93

-1.06%

RAMP

LiveRamp Holdings, Inc.

USD 32.46

-1.55%

VCYT

Veracyte, Inc.

USD 26.45

-1.60%

BAVA.CO

Bavarian Nordic A/S

USD 26.28

-0.67%

300199.SZ

Hybio Pharmaceutical Co., Ltd.

USD 2.29

-0.21%

StockViz Staff

June 26, 2025

Any question? Send us an email